CORRECTION: CDC COCA Call: CDC and FDA Update: Interim Clinical Considerations for Monkeypox Vaccination
|
|
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the JYNNEOS vaccine. The EUA allows healthcare providers to administer the vaccine by intradermal injection for individuals 18 years of age and older who are at high risk for monkeypox infection, which will result in up to a five-fold increase in the total number of doses available for use. In addition, the Centers for Disease Control and Prevention (CDC) has released Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak that provides guidance for using the alternative (intradermal) regimen, as well as the standard (subcutaneous) regimen for JYNNEOS vaccine.
During this COCA Call, presenters from FDA and CDC will provide updates on FDA’s EUA of the JYNNEOS vaccine and CDC’s Interim Clinical Considerations for using the JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak. Presenters will also provide training on how to administer the vaccines using the interim clinical considerations.
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.
The slide set will be available on the day of the call on the COCA Call webpage under Call Materials.
Continuing Education (CE) will not be offered for this COCA Call.
Call Information
|
